Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Caribou Biosciences (CRBU) Profit After Tax (2020 - 2025)

Historic Profit After Tax for Caribou Biosciences (CRBU) over the last 6 years, with Q3 2025 value amounting to -$27.5 million.

  • Caribou Biosciences' Profit After Tax rose 2057.43% to -$27.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$157.1 million, marking a year-over-year decrease of 608.7%. This contributed to the annual value of -$149.1 million for FY2024, which is 4608.11% down from last year.
  • According to the latest figures from Q3 2025, Caribou Biosciences' Profit After Tax is -$27.5 million, which was up 2057.43% from -$54.1 million recorded in Q2 2025.
  • Over the past 5 years, Caribou Biosciences' Profit After Tax peaked at -$10.0 million during Q3 2023, and registered a low of -$54.1 million during Q2 2025.
  • Moreover, its 5-year median value for Profit After Tax was -$27.5 million (2025), whereas its average is -$28.4 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 66447.65% in 2021, then skyrocketed by 6246.48% in 2023.
  • Quarter analysis of 5 years shows Caribou Biosciences' Profit After Tax stood at -$18.5 million in 2021, then plummeted by 46.05% to -$27.0 million in 2022, then dropped by 27.85% to -$34.5 million in 2023, then dropped by 2.85% to -$35.5 million in 2024, then rose by 22.38% to -$27.5 million in 2025.
  • Its last three reported values are -$27.5 million in Q3 2025, -$54.1 million for Q2 2025, and -$40.0 million during Q1 2025.